FDA Approves Cobenfy, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Bristol Myers Squibb announced the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
- Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors. Schizophrenia is estimated to impact approximately 2.8 million people in the United States. Symptoms typically first appear in early adulthood and present differently.
- While the current standard of care can be effective in managing symptoms of schizophrenia, up to 60% of people experience inadequate improvement in symptoms or intolerable side effects during therapy, making symptoms difficult to diagnose and manage.
Source: Bristol Myers Squibb
